fbpx

Day

December 4, 2017
Funds will support Phase 2 study of Reltecimod for Acute Kidney Injury; Phase 3 study of Reltecimod for Necrotizing Soft Tissue Infections (“flesh eating bacteria”) ongoing Ness Ziona, Israel and Chapel Hill, NC – December 4, 2017 – Atox Bio, a clinical stage biotechnology company developing novel therapies for critically ill patients, today announced that it has raised...
Funds will support Phase 2 study of Reltecimod for Acute Kidney Injury; Phase 3 study of Reltecimod for Necrotizing Soft Tissue Infections (“flesh eating bacteria”) ongoing Ness Ziona, Israel and Chapel Hill, NC – December 4, 2017 – Atox Bio, a clinical stage biotechnology company developing novel therapies for critically ill patients, today announced that...

News

Professor wants to develop a radioactive precision missile to target brain cancer
21. February 2020
New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge